Saira Sanjida1, Monika Janda1, David Kissane2, Joanne Shaw3, Sallie-Anne Pearson4, Tracey DiSipio1, Jeremy Couper5,6. 1. School of Public Health and Social Work, Institute for Health and Biomedical Innovation, Queensland University of Technology, Brisbane, Australia. 2. Department of Psychiatry, Monash University, Melbourne, Australia. 3. Psycho-oncology Co-operative Research Group, School of Psychology, The University of Sydney, Sydney, Australia. 4. Faculty of Pharmacy, The University of Sydney, Sydney, Australia. 5. Department of Psychiatry, Peter MacCallum Cancer Centre, Melbourne, Australia. 6. Department of Psychiatry, University of Melbourne, Melbourne, Australia.
Abstract
BACKGROUND: Antidepressants are commonly used for the pharmacological treatment of depression. We aimed to summarise the prevalence of antidepressant prescription to cancer patients, and differences by study or patient characteristics. METHODS: PubMed, Embase, Web of Science, Scopus and psychINFO were searched using keywords 'psychotropic', 'antidepressants', 'prescription' and 'cancer'. Prevalence of antidepressants, type, dose and follow-up of antidepressants and prescriber details were extracted. RESULTS: Overall, 1537 articles between 1979 and February 2015 were found, 38 met the inclusion criteria and were reviewed according to PRISMA guidelines. The prevalence rate of prescribing antidepressants to cancer patients was 15.6% (95% CI = 13.3-18.3). Prescription was significantly less common in studies from Asia (7.4%; 95% CI = 4.3-12.5), more common in female (22.6%; 95% CI = 16.0-31.0) or breast cancer patients (22.6%; 95% CI = 16.0-30.9). Selective serotonin reuptake inhibitors were the most frequently prescribed antidepressants. General practitioners and psychiatrists, followed by oncologists, were identified as the major providers of antidepressant prescriptions to cancer patients. Few studies reported the exact dose, length of time drugs were prescribed for or follow-up regimens. CONCLUSIONS: There is considerable variation in the prescribing patterns of antidepressants across the world, with few studies reporting robust data on exact dose or follow-up regimens. Prospective studies that monitor antidepressant prescribing, including details of reasons for prescribing and the healthcare providers involved, dose, change in dose or type of medication and follow-up are needed to ascertain whether patients are being treated optimally and if side effects or drug-drug interactions are identified and managed.
BACKGROUND: Antidepressants are commonly used for the pharmacological treatment of depression. We aimed to summarise the prevalence of antidepressant prescription to cancerpatients, and differences by study or patient characteristics. METHODS: PubMed, Embase, Web of Science, Scopus and psychINFO were searched using keywords 'psychotropic', 'antidepressants', 'prescription' and 'cancer'. Prevalence of antidepressants, type, dose and follow-up of antidepressants and prescriber details were extracted. RESULTS: Overall, 1537 articles between 1979 and February 2015 were found, 38 met the inclusion criteria and were reviewed according to PRISMA guidelines. The prevalence rate of prescribing antidepressants to cancerpatients was 15.6% (95% CI = 13.3-18.3). Prescription was significantly less common in studies from Asia (7.4%; 95% CI = 4.3-12.5), more common in female (22.6%; 95% CI = 16.0-31.0) or breast cancerpatients (22.6%; 95% CI = 16.0-30.9). Selective serotonin reuptake inhibitors were the most frequently prescribed antidepressants. General practitioners and psychiatrists, followed by oncologists, were identified as the major providers of antidepressant prescriptions to cancerpatients. Few studies reported the exact dose, length of time drugs were prescribed for or follow-up regimens. CONCLUSIONS: There is considerable variation in the prescribing patterns of antidepressants across the world, with few studies reporting robust data on exact dose or follow-up regimens. Prospective studies that monitor antidepressant prescribing, including details of reasons for prescribing and the healthcare providers involved, dose, change in dose or type of medication and follow-up are needed to ascertain whether patients are being treated optimally and if side effects or drug-drug interactions are identified and managed.
Authors: Michelle B Riba; Kristine A Donovan; Barbara Andersen; IIana Braun; William S Breitbart; Benjamin W Brewer; Luke O Buchmann; Matthew M Clark; Molly Collins; Cheyenne Corbett; Stewart Fleishman; Sofia Garcia; Donna B Greenberg; Rev George F Handzo; Laura Hoofring; Chao-Hui Huang; Robin Lally; Sara Martin; Lisa McGuffey; William Mitchell; Laura J Morrison; Megan Pailler; Oxana Palesh; Francine Parnes; Janice P Pazar; Laurel Ralston; Jaroslava Salman; Moreen M Shannon-Dudley; Alan D Valentine; Nicole R McMillian; Susan D Darlow Journal: J Natl Compr Canc Netw Date: 2019-10-01 Impact factor: 11.908
Authors: Saira Sanjida; Kelly Mulvogue; Joanne Shaw; Jeremy Couper; David Kissane; Sallie-Anne Pearson; Melanie A Price; Monika Janda Journal: Support Care Cancer Date: 2017-09-19 Impact factor: 3.603
Authors: Gaia Pocobelli; Onchee Yu; Rebecca A Ziebell; Erin J Aiello Bowles; Monica M Fujii; Andrew T Sterrett; Jennifer M Boggs; Lu Chen; Denise M Boudreau; Debra P Ritzwoller; Rebecca A Hubbard; Jessica Chubak Journal: Psychooncology Date: 2019-02-14 Impact factor: 3.894
Authors: Franziska Holtdirk; Anja Mehnert; Mario Weiss; Johannes Mayer; Björn Meyer; Peter Bröde; Maren Claus; Carsten Watzl Journal: PLoS One Date: 2021-05-07 Impact factor: 3.240
Authors: Moritz Philipp Günther; Johannes Kirchebner; Jan Ben Schulze; Roland von Känel; Sebastian Euler Journal: Eur J Cancer Care (Engl) Date: 2022-02-09 Impact factor: 2.328